TickerGraveyard
TickerGraveyard

GNFT

Delisted
Genfit S.A.

GNFT — Post-Mortem

Genfit S.A., a French biotechnology firm focused on liver diseases, reached its share price peak of approximately $30 in late 2020 due to positive investor sentiment surrounding its clinical trials and innovations. However, following a series of setbacks in its clinical development pipeline, confidence waned, leading to a substantial decline in share value, which fell to around $12 by early 2022. Ultimately, Genfit chose to voluntarily withdraw from the Nasdaq Global Select Market, as indicated by Form 25 filed on November 10, 2025, signaling a strategic restructuring and a shift away from the U.S. capital markets. This delisting highlights the complex challenges biotech firms face, particularly regarding the execution of clinical trials and market communication.

On November 10, 2025, Genfit S.A. was delisted from Nasdaq following its voluntary withdrawal of American Depository Shares, impacted by setbacks in clinical trials.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Genfit S.A. was incorporated in France, primarily known for its focus on liver diseases and metabolic disorders.

Peak

The company's peak occurred in late 2020 when its share price reached approximately $30, bolstered by investor optimism surrounding its clinical pipeline and potential innovations in biotechnology.

Turning Point

The turning point was marked in the second half of 2021, when clinical trials faced setbacks, leading to declining investor confidence and a significant drop in share price, down to around $12 by early 2022.

End

On November 10, 2025, Genfit S.A. was delisted from the Nasdaq Global Select Market as evidenced by Form 25, following its voluntary withdrawal from listing, which was part of a broader strategic realignment.

Impact

The delisting removed the company's American Depositary Shares from a major international exchange, significantly constraining its access to U.S. capital markets and diminishing its visibility to global investors.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Investors should assess the stability and progress of clinical trials when evaluating biotech companies, as failures can severely impact valuations.

  2. 2

    Strategic shifts must be communicated clearly to investors; ambiguity can lead to a rapid loss of confidence and decline in market capitalization.

  3. 3

    Voluntary delisting can reflect broader strategic challenges; it should be closely analyzed as part of an overall assessment of a company's health.

Frequently Asked Questions

Why was Genfit S.A. delisted from Nasdaq?
Genfit S.A. voluntarily withdrew its American Depository Shares from listing, as stated in Form 25 filed on November 10, 2025.
What were the circumstances leading to the delisting?
The delisting followed a series of setbacks in clinical trials and a significant drop in investor confidence in the company's prospects.
What is the future for Genfit S.A. following the delisting?
Post-delisting, Genfit S.A. may choose to focus on its operations in Europe and realign its strategic objectives away from U.S. market dependence.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: